The efficacy of ICI therapy, mainly anti-PD-1 monotherapy, in 414 patients from 11 centers, suggests that antibiotics (beta-lactams or quinolones) administered 30 days pre- or post-ICI initiation in HCC are linked with extended progression-free survival (79). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.